Adults with MS had lower annualized relapse rates with diroximel fumarate vs. dimethyl fumarate treatment at 1 and 2 years, ...
After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active ...
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of ...
This transcript has been edited for clarity. John Kane, MD: I am Dr John Kane. I am a professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New ...
Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...
Helping a loved one manage their addiction doesn’t stop in recovery. With nearly 28 million Americans who report they are currently recovering, addiction requires the same long-term care and ...
Relapse, or recurrence, occurs when multiple myeloma symptoms return, such as bone pain, fatigue, and kidney problems. It’s possible to live for many years after a relapse of multiple myeloma. Outlook ...
Teclistamab (Tecvayli; Johnson & Johnson) appears poised to move into earlier lines of care as a monotherapy, as bispecific antibodies made big news in the treatment of blood cancers and disorders on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results